Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1993 1
1995 1
1998 2
1999 2
2000 4
2001 3
2002 4
2003 3
2004 1
2005 4
2006 2
2007 1
2008 1
2009 10
2010 7
2011 5
2012 7
2013 8
2014 6
2015 3
2016 6
2017 11
2018 6
2019 5
2020 4
2021 7
2022 5
2023 6
2024 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

116 results

Results by year

Filters applied: . Clear all
Page 1
Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia.
Kadia TM, Reville PK, Wang X, Rausch CR, Borthakur G, Pemmaraju N, Daver NG, DiNardo CD, Sasaki K, Issa GC, Ohanian M, Montalban-Bravo G, Short NJ, Jain N, Ferrajoli A, Bhalla KN, Jabbour E, Takahashi K, Malla R, Quagliato K, Kanagal-Shamanna R, Popat UR, Andreeff M, Garcia-Manero G, Konopleva MY, Ravandi F, Kantarjian HM. Kadia TM, et al. Among authors: bhalla kn. J Clin Oncol. 2022 Nov 20;40(33):3848-3857. doi: 10.1200/JCO.21.02823. Epub 2022 Jun 15. J Clin Oncol. 2022. PMID: 35704787 Free PMC article. Clinical Trial.
Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1.
Fiskus W, Mill CP, Birdwell C, Davis JA, Das K, Boettcher S, Kadia TM, DiNardo CD, Takahashi K, Loghavi S, Soth MJ, Heffernan T, McGeehan GM, Ruan X, Su X, Vakoc CR, Daver N, Bhalla KN. Fiskus W, et al. Among authors: bhalla kn. Blood Cancer J. 2023 Apr 13;13(1):53. doi: 10.1038/s41408-023-00826-6. Blood Cancer J. 2023. PMID: 37055414 Free PMC article.
Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies.
DiNardo CD, Rausch CR, Benton C, Kadia T, Jain N, Pemmaraju N, Daver N, Covert W, Marx KR, Mace M, Jabbour E, Cortes J, Garcia-Manero G, Ravandi F, Bhalla KN, Kantarjian H, Konopleva M. DiNardo CD, et al. Among authors: bhalla kn. Am J Hematol. 2018 Mar;93(3):401-407. doi: 10.1002/ajh.25000. Epub 2017 Dec 23. Am J Hematol. 2018. PMID: 29218851 Free article.
BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor.
Fiskus W, Piel J, Collins M, Hentemann M, Cuglievan B, Mill CP, Birdwell CE, Das K, Davis JA, Hou H, Jain A, Malovannaya A, Kadia TM, Daver N, Sasaki K, Takahashi K, Hammond D, Reville PK, Wang J, Loghavi S, Sen R, Ruan X, Su X, Flores LB, DiNardo CD, Bhalla KN. Fiskus W, et al. Among authors: bhalla kn. Blood. 2024 May 16;143(20):2059-2072. doi: 10.1182/blood.2023022832. Blood. 2024. PMID: 38437498
Targeting cistrome and dysregulated transcriptome of post-MPN sAML.
Verstovsek S, Fiskus W, Manshouri T, Bhalla KN. Verstovsek S, et al. Among authors: bhalla kn. Oncotarget. 2017 Oct 11;8(55):93301-93302. doi: 10.18632/oncotarget.21752. eCollection 2017 Nov 7. Oncotarget. 2017. PMID: 29212143 Free PMC article. No abstract available.
Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1.
Fiskus W, Daver N, Boettcher S, Mill CP, Sasaki K, Birdwell CE, Davis JA, Das K, Takahashi K, Kadia TM, DiNardo CD, Burrows F, Loghavi S, Khoury JD, Ebert BL, Bhalla KN. Fiskus W, et al. Among authors: bhalla kn. Leukemia. 2022 Nov;36(11):2729-2733. doi: 10.1038/s41375-022-01707-w. Epub 2022 Sep 23. Leukemia. 2022. PMID: 36151141 Free PMC article. No abstract available.
Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1.
Mill CP, Fiskus W, Das K, Davis JA, Birdwell CE, Kadia TM, DiNardo CD, Daver N, Takahashi K, Sasaki K, McGeehan GM, Ruan X, Su X, Loghavi S, Kantarjian H, Bhalla KN. Mill CP, et al. Among authors: bhalla kn. Leukemia. 2023 Jun;37(6):1336-1348. doi: 10.1038/s41375-023-01882-4. Epub 2023 Mar 28. Leukemia. 2023. PMID: 36977823 Free PMC article.
116 results